Firebrick Pharma Ltd Cash Flow Conversion Efficiency
Firebrick Pharma Ltd cash flow conversion efficiency. Based on the latest financial reports, Firebrick Pharma Ltd (FRE) has a cash flow conversion efficiency ratio of -0.543x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-1.05 Million ≈ $-745.48K USD) by net assets (AU$1.94 Million ≈ $1.37 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Firebrick Pharma Ltd (2019–2025)
Cash flow conversion efficiency of Firebrick Pharma Ltd from 2019 to 2025. This chart illustrates how Firebrick Pharma Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View FRE share price today for real-time trading data and today's change.
Firebrick Pharma Ltd Cash Flow Conversion Ratio Explained
Firebrick Pharma Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Firebrick Pharma Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Firebrick Pharma Ltd ranked by their cash flow conversion efficiency. Also see Firebrick Pharma Ltd (FRE) market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
WiMi Hologram Cloud Inc
NASDAQ:WIMI
|
0.044x |
|
BRITANNIA LIFE SCIENCES
F:L020
|
0.057x |
|
TFP Solutions Bhd
KLSE:0145
|
-0.142x |
|
Basel Medical Group Ltd Ordinary Shares
NASDAQ:BMGL
|
-0.250x |
|
Utilico Emerging Markets Ltd
LSE:UEM
|
0.009x |
|
RareX Limited
F:CK1
|
-0.102x |
|
Adamera Minerals Corp.
V:ADZ
|
-0.205x |
|
E Investment & Development
KO:093230
|
-0.020x |
Annual Cash Flow Conversion Efficiency for Firebrick Pharma Ltd (2019–2025)
The table below shows the annual cash flow conversion efficiency of Firebrick Pharma Ltd from 2019 to 2025. Review FRE financial flexibility index to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | AU$1.56 Million ≈ $1.10 Million |
AU$-1.78 Million ≈ $-1.26 Million |
-1.143x | -3.12% |
| 2024-06-30 | AU$2.12 Million ≈ $1.50 Million |
AU$-2.34 Million ≈ $-1.66 Million |
-1.109x | +52.54% |
| 2023-06-30 | AU$2.48 Million ≈ $1.75 Million |
AU$-5.78 Million ≈ $-4.09 Million |
-2.336x | -360.20% |
| 2022-06-30 | AU$8.28 Million ≈ $5.86 Million |
AU$-4.20 Million ≈ $-2.97 Million |
-0.508x | -202.88% |
| 2021-06-30 | AU$11.55 Million ≈ $8.17 Million |
AU$-1.94 Million ≈ $-1.37 Million |
-0.168x | +93.35% |
| 2020-06-30 | AU$390.60K ≈ $276.37K |
AU$-985.01K ≈ $-696.96K |
-2.522x | -155.58% |
| 2019-06-30 | AU$1.08 Million ≈ $763.34K |
AU$-1.06 Million ≈ $-753.18K |
-0.987x | -- |
About Firebrick Pharma Ltd
Firebrick Pharma Limited engages in the development and commercialization of povidone-iodine (PVP-I) products under the Nasodine brand in Asia, North America, Europe, and internationally. It offers nasal spray PVP-I products for the treatment of common cold. The company was incorporated in 2012 and is based in Melbourne, Australia.